109 related articles for article (PubMed ID: 28680759)
1. Parallel profiling of immune infiltrate subsets in uveal melanoma versus cutaneous melanoma unveils similarities and differences: A pilot study.
Qin Y; Petaccia de Macedo M; Reuben A; Forget MA; Haymaker C; Bernatchez C; Spencer CN; Gopalakrishnan V; Reddy S; Cooper ZA; Fulbright OJ; Ramachandran R; Wahl A; Flores E; Thorsen ST; Tavera RJ; Conrad C; Williams MD; Tetzlaff MT; Wang WL; Gombos DS; Esmaeli B; Amaria RN; Hwu P; Wargo JA; Lazar AJ; Patel SP
Oncoimmunology; 2017; 6(6):e1321187. PubMed ID: 28680759
[TBL] [Abstract][Full Text] [Related]
2. Uveal Versus Cutaneous Melanoma; Same Origin, Very Distinct Tumor Types.
van der Kooij MK; Speetjens FM; van der Burg SH; Kapiteijn E
Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31248118
[TBL] [Abstract][Full Text] [Related]
3. Uveal melanoma immunogenomics predict immunotherapy resistance and susceptibility.
Leonard-Murali S; Bhaskarla C; Yadav GS; Maurya SK; Galiveti CR; Tobin JA; Kann RJ; Ashwat E; Murphy PS; Chakka AB; Soman V; Cantalupo PG; Zhuo X; Vyas G; Kozak DL; Kelly LM; Smith E; Chandran UR; Hsu YS; Kammula US
Nat Commun; 2024 Apr; 15(1):2863. PubMed ID: 38627362
[TBL] [Abstract][Full Text] [Related]
4. Clinical Trials in Metastatic Uveal Melanoma: Immunotherapy.
Orloff M
Ocul Oncol Pathol; 2021 Jun; 7(3):168-176. PubMed ID: 34307327
[TBL] [Abstract][Full Text] [Related]
5. IL-6-Driven Autocrine Lactate Promotes Immune Escape of Uveal Melanoma.
Gong C; Yang M; Long H; Liu X; Xu Q; Qiao L; Dong H; Liu Y; Li S
Invest Ophthalmol Vis Sci; 2024 Mar; 65(3):37. PubMed ID: 38551584
[TBL] [Abstract][Full Text] [Related]
6. Uveal Melanoma Metastasis.
Rossi E; Croce M; Reggiani F; Schinzari G; Ambrosio M; Gangemi R; Tortora G; Pfeffer U; Amaro A
Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830841
[TBL] [Abstract][Full Text] [Related]
7. Molecular Insights and Emerging Strategies for Treatment of Metastatic Uveal Melanoma.
Mallone F; Sacchetti M; Lambiase A; Moramarco A
Cancers (Basel); 2020 Sep; 12(10):. PubMed ID: 32992823
[TBL] [Abstract][Full Text] [Related]
8. Immunobiology of Uveal Melanoma: State of the Art and Therapeutic Targets.
Basile MS; Mazzon E; Fagone P; Longo A; Russo A; Fallico M; Bonfiglio V; Nicoletti F; Avitabile T; Reibaldi M
Front Oncol; 2019; 9():1145. PubMed ID: 31750244
[TBL] [Abstract][Full Text] [Related]
9. Analysis of uveal melanoma scRNA sequencing data identifies neoplastic-immune hybrid cells that exhibit metastatic potential.
Anderson AN; Conley P; Klocke CD; Sengupta SK; Robinson TL; Fan Y; Jones JA; Gibbs SL; Skalet AH; Wu G; Wong MH
bioRxiv; 2023 Oct; ():. PubMed ID: 37961378
[TBL] [Abstract][Full Text] [Related]
10. Pilot Study of Circulating Tumor Cells in Early-Stage and Metastatic Uveal Melanoma.
Anand K; Roszik J; Gombos D; Upshaw J; Sarli V; Meas S; Lucci A; Hall C; Patel S
Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31226786
[TBL] [Abstract][Full Text] [Related]
11. So Close, yet so Far: Discrepancies between Uveal and Other Melanomas. A Position Paper from UM Cure 2020.
Rodrigues M; Koning L; Coupland SE; Jochemsen AG; Marais R; Stern MH; Valente A; Barnhill R; Cassoux N; Evans A; Galloway I; Jager MJ; Kapiteijn E; Romanowska-Dixon B; Ryll B; Roman-Roman S; Piperno-Neumann S;
Cancers (Basel); 2019 Jul; 11(7):. PubMed ID: 31336679
[TBL] [Abstract][Full Text] [Related]
12. Differences in Uveal Melanoma Age-Standardized Incidence Rates in Two Eastern States of Australia Are Driven by Differences in Rurality and Ultraviolet Radiation.
Chalada M; Ramlogan-Steel CA; Dhungel BP; Goh AY; Gardiner S; Layton CJ; Steel JC
Cancers (Basel); 2021 Nov; 13(23):. PubMed ID: 34885004
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Maintained Response to Selective Internal Radiation Therapy in an Oligometastatic Uveal Melanoma Patient Treated with Concomitant Anti-PD-1 Therapy.
Proietti I; Skroza N; Filippi L; Bernardini N; Mambrin A; Tolino E; Rossi G; Marchesiello A; Marraffa F; Volpe S; Bagni O; Potenza C
Life (Basel); 2021 Jul; 11(7):. PubMed ID: 34357064
[TBL] [Abstract][Full Text] [Related]
14. Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma.
Reuben A; Spencer CN; Prieto PA; Gopalakrishnan V; Reddy SM; Miller JP; Mao X; De Macedo MP; Chen J; Song X; Jiang H; Chen PL; Beird HC; Garber HR; Roh W; Wani K; Chen E; Haymaker C; Forget MA; Little LD; Gumbs C; Thornton RL; Hudgens CW; Chen WS; Austin-Breneman J; Sloane RS; Nezi L; Cogdill AP; Bernatchez C; Roszik J; Hwu P; Woodman SE; Chin L; Tawbi H; Davies MA; Gershenwald JE; Amaria RN; Glitza IC; Diab A; Patel SP; Hu J; Lee JE; Grimm EA; Tetzlaff MT; Lazar AJ; Wistuba II; Clise-Dwyer K; Carter BW; Zhang J; Futreal PA; Sharma P; Allison JP; Cooper ZA; Wargo JA
NPJ Genom Med; 2017; 2():. PubMed ID: 28819565
[TBL] [Abstract][Full Text] [Related]
15. Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma.
Robertson AG; Shih J; Yau C; Gibb EA; Oba J; Mungall KL; Hess JM; Uzunangelov V; Walter V; Danilova L; Lichtenberg TM; Kucherlapati M; Kimes PK; Tang M; Penson A; Babur O; Akbani R; Bristow CA; Hoadley KA; Iype L; Chang MT; ; Cherniack AD; Benz C; Mills GB; Verhaak RGW; Griewank KG; Felau I; Zenklusen JC; Gershenwald JE; Schoenfield L; Lazar AJ; Abdel-Rahman MH; Roman-Roman S; Stern MH; Cebulla CM; Williams MD; Jager MJ; Coupland SE; Esmaeli B; Kandoth C; Woodman SE
Cancer Cell; 2017 Aug; 32(2):204-220.e15. PubMed ID: 28810145
[TBL] [Abstract][Full Text] [Related]
16. Frequent GNAQ, GNA11, and EIF1AX Mutations in Iris Melanoma.
Scholz SL; Möller I; Reis H; Süßkind D; van de Nes JAP; Leonardelli S; Schilling B; Livingstone E; Schimming T; Paschen A; Sucker A; Murali R; Steuhl KP; Schadendorf D; Westekemper H; Griewank KG
Invest Ophthalmol Vis Sci; 2017 Jul; 58(9):3464-3470. PubMed ID: 28700778
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function.
Lee YH; Martin-Orozco N; Zheng P; Li J; Zhang P; Tan H; Park HJ; Jeong M; Chang SH; Kim BS; Xiong W; Zang W; Guo L; Liu Y; Dong ZJ; Overwijk WW; Hwu P; Yi Q; Kwak L; Yang Z; Mak TW; Li W; Radvanyi LG; Ni L; Liu D; Dong C
Cell Res; 2017 Aug; 27(8):1034-1045. PubMed ID: 28685773
[TBL] [Abstract][Full Text] [Related]
18. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.
Overman MJ; McDermott R; Leach JL; Lonardi S; Lenz HJ; Morse MA; Desai J; Hill A; Axelson M; Moss RA; Goldberg MV; Cao ZA; Ledeine JM; Maglinte GA; Kopetz S; André T
Lancet Oncol; 2017 Sep; 18(9):1182-1191. PubMed ID: 28734759
[TBL] [Abstract][Full Text] [Related]
19. Immunogenic profiling of metastatic uveal melanoma discerns a potential signature related to prognosis.
Wang J; Liu M; Sun J; Zhang Z
J Cancer Res Clin Oncol; 2024 Jan; 150(1):23. PubMed ID: 38246894
[TBL] [Abstract][Full Text] [Related]
20. The immune checkpoint VISTA is associated with prognosis in patients with malignant uveal melanoma.
Issam Salah NEI; Marnissi F; Lakhdar A; Karkouri M; ElBelhadji M; Badou A
Front Immunol; 2023; 14():1225140. PubMed ID: 37662962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
